| Date Filed | Type | Description |
| 08/14/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/02/2023 |
6-K
| Quarterly results |
| 07/31/2023 |
6-K
| Quarterly results |
| 07/25/2023 |
6-K
| Quarterly results |
| 07/25/2023 |
6-K
| Quarterly results |
| 07/12/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox IRVINE, CA Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling. Mr. Doody has represented Nymox a..." |
|
| 06/29/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/29/2023 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
| 05/18/2023 |
4/A
| Robinson James George (10% Owner) has filed a Form 4 on NYMOX PHARMACEUTICAL CORP|
Txns:
| Bought 40,000 shares
@ $0.45, valued at
$18k
|
|
| 05/12/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/02/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/31/2023 |
NT 20-F
| Form NT 20-F - Notification of inability to timely file Form 20-F: |
| 01/06/2023 |
6-K
| Quarterly results |
| 11/16/2022 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
| 11/16/2022 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
| 11/14/2022 |
6-K
| Quarterly results |
| 11/10/2022 |
6-K
| Quarterly results |
| 08/15/2022 |
6-K
| Quarterly results |
| 07/07/2022 |
6-K
| Quarterly results |
| 05/13/2022 |
6-K
| Quarterly results |
| 05/06/2022 |
4
| Robinson James George (Director) has filed a Form 4 on NYMOX PHARMACEUTICAL CORP|
Txns:
| Bought 1,151,515 shares
@ $1.65, valued at
$1.9M
Bought 1,151,515 warrants
@ $2, valued at
$2.3M
|
|
| 04/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/30/2022 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/29/2022 |
F-3
| Form F-3 - Registration statement by foreign private issuers: |
| 03/22/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/22/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/09/2021 |
F-3
| Form F-3 - Registration statement by foreign private issuers: |
| 11/22/2021 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
| 11/19/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/12/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/13/2021 |
6-K
| Quarterly results |
| 06/11/2021 |
20-F/A
| Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] |
| 05/21/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|